Product image of Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po) supplied by GNH India

Imovax Polio

Active Ingredient:
Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po
Origin:
EU

Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Poliovirus (Inactivated) Type 1 (Mahoney Strain), the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It prevents poliomyelitis caused by poliovirus types 1, 2, and 3.

GNH India supplies Imovax Polio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imovax Polio is an inactivated poliovirus vaccine used to prevent poliomyelitis, a viral infection of the nervous system.

  • Poliomyelitis (type 1): Induces immunity to prevent infection with type 1 poliovirus.
  • Poliomyelitis (type 2): Induces immunity to prevent infection with type 2 poliovirus.
  • Poliomyelitis (type 3): Induces immunity to prevent infection with type 3 poliovirus.

How It Works

  • The vaccine contains chemically inactivated whole poliovirus particles of types 1, 2 and 3. After intramuscular or subcutaneous injection, antigen‑presenting cells process the viral proteins and present them to T‑cells, stimulating B‑cell production of neutralising antibodies that block viral attachment and replication, thereby establishing active immunity against poliovirus infection.

Side Effects

Common side effects are usually mild and transient, reflecting the local immune response to the injected antigen.

Common Side Effects

  • Pain at the injection site: mild to moderate discomfort.
  • Redness or swelling: localized erythema around the injection area.
  • Fever: low‑grade temperature rise within 24‑48 hours.
  • Headache: mild tension‑type headache.
  • Fatigue: temporary tiredness after vaccination.
  • Irritability (in children): brief fussiness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare autoimmune neuropathy.
  • Seizures: infrequent neurologic event.
  • Severe hypotension: sudden drop in blood pressure.
  • Myocarditis: inflammation of heart muscle.
  • Persistent high fever: >39 °C lasting more than 48 hours.

Precautions & Warnings

Before administering Imovax Polio, healthcare professionals should consider several safety measures.

  • Screen for contraindications: known hypersensitivity to any vaccine component.
  • Assess immune status: immunocompromised individuals may have reduced response.
  • Pregnancy: safety not established; weigh benefits versus potential risks.
  • Concurrent vaccines: may be given according to recommended immunisation schedule.
  • Observe after injection: monitor for immediate allergic reactions.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Imovax Polio may interact with other agents that influence immune response or vaccine efficacy.

Major Interactions (Avoid)

  • Live viral vaccines: concurrent administration may reduce immune response to either product.
  • Immunoglobulin therapy: may neutralise vaccine antigens and diminish effectiveness.
  • Blood products: can interfere with antibody formation.

Moderate Interactions (Monitor Closely)

  • Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever.
  • Corticosteroids: may blunt antibody response when used at high doses.

Frequently Asked Questions

Imovax Polio is an inactivated poliovirus vaccine indicated for the prevention of poliomyelitis caused by poliovirus types 1, 2 and 3. It is administered to individuals as part of routine immunisation programmes to establish protective immunity against these viral strains.

The inactivated poliovirus particles cannot replicate but retain their antigenic structure. After injection, the immune system recognises these antigens, activates T‑cells, and stimulates B‑cells to produce neutralising antibodies that block future infection by the live poliovirus.

The specific dose and schedule are determined by the prescribing clinician based on age, immunisation history and local guidelines. Healthcare providers select the appropriate volume and route (intramuscular or subcutaneous) for each patient.

Safety data in pregnancy are limited, and the product is classified as having an unknown pregnancy category. The decision to vaccinate a pregnant or breastfeeding individual should be made by a qualified healthcare professional after weighing potential benefits against any theoretical risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imovax Polio is an inactivated (killed) vaccine, whereas oral polio vaccine (OPV) contains live attenuated virus. Inactivated vaccines cannot cause vaccine‑derived poliovirus infection and are preferred in settings where OPV‑related risks must be avoided, though both achieve comparable protective immunity when administered correctly.

The vaccine must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Vials should be kept in their original packaging until use to maintain potency and sterility.

Imovax Polio is supplied as a sterile injectable solution. It is given by a trained healthcare professional via intramuscular or subcutaneous injection, typically in the deltoid or anterolateral thigh muscle, following aseptic technique.

Serious adverse events are rare but may include anaphylactic reactions, Guillain‑Barré syndrome, seizures, severe hypotension, myocarditis, and persistent high fever. Immediate medical attention is required if any of these symptoms develop after vaccination.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a previous severe reaction to an inactivated poliovirus vaccine, should not receive Imovax Polio. Contraindications are assessed by the prescribing clinician before administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT